What the FDA decides this month, and the GLP-1 bone-loss story everyone's about to misread
The honest read on peptides, hormones, and midlife — what the evidence supports, what it doesn't, and what's just good marketing.
The big vote is days away — and it's not the green light it's being sold as
On July 23–24, an FDA advisory committee votes on seven peptides (BPC-157, KPV, TB-500, MOTS-c, then DSIP, Semax, Epitalon). The headlines say "peptides going legal in 2026." The fine print says otherwise: this is an advisory vote, and even a yes kicks off a formal rulemaking process that, by most legal estimates, takes a year or more. Earliest realistic pharmacy availability is 2027. Anyone telling you these hit shelves next month is selling something.
The history nobody quotes. The same committee reviewed peptides in 2024 and rejected every single one — CJC-1295 went down 0-13, and Thymosin Alpha-1, the one with the best clinical record, lost 4-17. A "yes" this round is plausible but far from given. Temper the optimism.
If you want to weigh in: the public comment docket is open. Comments by July 9 reach the committee directly; by July 22, they reach the FDA. You don't have to be an expert to file one — patient need is part of what they weigh.
A second peptide hearing is coming — and this one's for you
Easy to miss in the July noise: the FDA has committed to a second review before February 2027, covering five more peptides. One of them is GHK-Cu — the copper peptide that's actually relevant to midlife skin, not the recovery-focused compounds dominating the July docket. So the regulatory story keeps landing closer to home. We'll track it.
The reframe worth keeping in your pocket: there are really three different things hiding under the word "peptide" — FDA-approved drugs (the GLP-1s, rigorously studied), compoundable peptides (legal but not FDA-approved, evidence all over the map), and gray-market "research" peptides (unregulated, often unverified). Most of the confusion — and most of the marketing — comes from blurring these together. When someone says "peptides are proven," your first question is: which kind?
This week's "perfect storm" headline — read it carefully before you panic or dismiss it
New coverage is highlighting a real concern: menopause already drives bone loss (~1% of bone density a year as estrogen drops), and GLP-1 weight loss can add to it — because any fast weight loss sheds some bone and muscle, not just fat. One analysis put osteoporosis at ~4% of GLP-1 users versus ~3% of non-users. Real signal, worth knowing.
But here's the honest framing the scary version skips: this isn't a reason to write off GLP-1s, and it isn't a reason to ignore the risk. It's a reason to do the foundation work that protects you either way — resistance training and enough protein, which research shows meaningfully blunt the muscle-and-bone loss. One trial found exercise plus a GLP-1 preserved hip, spine, and forearm density despite bigger weight loss. The drug isn't the whole story; what you do alongside it is.
Which is the whole Peptune thesis in one example. Hormones are the floodlight, peptides the spotlight — but underneath both is the foundation: sleep, protein, strength, the unglamorous stuff. A GLP-1 without the strength work is a different, riskier proposition than a GLP-1 with it. If you're over 50 and starting one, a baseline DEXA scan and a strength program aren't optional extras. They're the point.
Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.
← All issues